| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence
Affiliations of authors: The VA Outcomes Group, White River Junction, VT (HP, HGW); and the Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH (HGW)
Correspondence to: Heiko Pohl, MD, VA Outcomes Group (111B), Department of Veterans Affairs Medical Center, White River Junction, VT 0500 (e-mail: heiko.pohl{at}dartmouth.edu and h.gilbert.welch{at}dartmouth.edu)
Background: The incidence of esophageal adenocarcinoma is rising dramatically. This increase may reflect increased disease burden, reclassification of related cancers, or overdiagnosis resulting from increased diagnostic intensity, particularly upper endoscopy for patients with gastroesophageal reflux disease or Barrett esophagus. Methods: We used the National Cancer Institutes Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers. Results: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer. Reclassification of squamous cell carcinoma is an unlikely explanation for the rise in incidence, because the anatomic distribution of esophageal cancer in general has changed. The only location with increased incidence is the lower third of the esophagusthe site where adenocarcinoma typically arises. Reclassification of adjacent gastric cancer is also unlikely because its incidence has also increased. Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence. Conclusion: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
Correspondence about this Article
- Re: The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence
- David Forman
J Natl Cancer Inst 2005 97: 1013-1014.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
![]() |
E. L. Kwak, T. S. Hong, D. L. Berger, D. G. Forcione, R. N. Uppot, and G. Y. Lauwers Case 19-2009 -- A 63-Year-Old Woman with Carcinoma of the Gastroesophageal Junction N. Engl. J. Med., June 18, 2009; 360(25): 2656 - 2664. [Full Text] [PDF] |
||||
![]() |
N. J. Shaheen, P. Sharma, B. F. Overholt, H. C. Wolfsen, R. E. Sampliner, K. K. Wang, J. A. Galanko, M. P. Bronner, J. R. Goldblum, A. E. Bennett, et al. Radiofrequency Ablation in Barrett's Esophagus with Dysplasia N. Engl. J. Med., May 28, 2009; 360(22): 2277 - 2288. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.G.H.M. Bergman Radiofrequency Ablation -- Great for Some or Justified for Many? N. Engl. J. Med., May 28, 2009; 360(22): 2353 - 2355. [Full Text] [PDF] |
||||
![]() |
T. G. Paulson, C. C. Maley, X. Li, H. Li, C. A. Sanchez, D. L. Chao, R. D. Odze, T. L. Vaughan, P. L. Blount, and B. J. Reid Chromosomal Instability and Copy Number Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma Clin. Cancer Res., May 15, 2009; 15(10): 3305 - 3314. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Sturmey, C. P. Wild, and L. J. Hardie Removal of red light minimizes methylene blue-stimulated DNA damage in oesophageal cells: implications for chromoendoscopy Mutagenesis, May 1, 2009; 24(3): 253 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Cescon, P. A. Bradbury, K. Asomaning, J. Hopkins, R. Zhai, W. Zhou, Z. Wang, M. Kulke, L. Su, C. Ma, et al. p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis Clin. Cancer Res., May 1, 2009; 15(9): 3103 - 3109. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. RAWNAQ, H. KLEINHANS, M. UTO, P. G. SCHURR, U. REICHELT, G. CATALDEGIRMEN, K. A. GAWAD, E. F. YEKEBAS, M. SCHACHNER, J. R. IZBICKI, et al. Subset of Esophageal Adenocarcinoma Expresses Adhesion Molecule L1 in Contrast to Squamous Cell Carcinoma Anticancer Res, April 1, 2009; 29(4): 1195 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C Whiteman Hot tea and increased risk of oesophageal cancer BMJ, March 26, 2009; 338(mar26_2): b610 - b610. [Full Text] |
||||
![]() |
O. M Thompson, S. A. Beresford, E. A Kirk, and T. L Vaughan Vegetable and fruit intakes and risk of Barrett's esophagus in men and women Am. J. Clinical Nutrition, March 1, 2009; 89(3): 890 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
D A Corley, A Kubo, T R Levin, G Block, L Habel, G Rumore, C Quesenberry, and P Buffler Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006 Gut, February 1, 2009; 58(2): 182 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hormi-Carver, X. Zhang, H. Y. Zhang, R. H. Whitehead, L. S. Terada, S. J. Spechler, and R. F. Souza Unlike Esophageal Squamous Cells, Barrett's Epithelial Cells Resist Apoptosis by Activating the Nuclear Factor-{kappa}B Pathway Cancer Res., January 15, 2009; 69(2): 672 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Pohl, T Rosch, M Vieth, M Koch, V Becker, M Anders, A C Khalifa, and A Meining Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus Gut, December 1, 2008; 57(12): 1648 - 1653. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, P. C. Galipeau, C. A. Sanchez, P. L. Blount, C. C. Maley, J. Arnaudo, D. A. Peiffer, D. Pokholok, K. L. Gunderson, and B. J. Reid Single Nucleotide Polymorphism-Based Genome-Wide Chromosome Copy Change, Loss of Heterozygosity, and Aneuploidy in Barrett's Esophagus Neoplastic Progression Cancer Prevention Research, November 1, 2008; 1(6): 413 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Kahrilas Gastroesophageal Reflux Disease N. Engl. J. Med., October 16, 2008; 359(16): 1700 - 1707. [Full Text] [PDF] |
||||
![]() |
C. E. Kight Nutrition Considerations in Esophagectomy Patients Nutr Clin Pract, October 1, 2008; 23(5): 521 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Ajani, K. Winter, R. Komaki, D. P. Kelsen, B. D. Minsky, Z. Liao, J. Bradley, M. Fromm, D. Hornback, and C. G. Willett Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG 0113 J. Clin. Oncol., October 1, 2008; 26(28): 4551 - 4556. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Blaser Disappearing Microbiota: Helicobacter pylori Protection against Esophageal Adenocarcinoma Cancer Prevention Research, October 1, 2008; 1(5): 308 - 311. [Full Text] [PDF] |
||||
![]() |
G. J. S. Jenkins, J. Cronin, A. Alhamdani, N. Rawat, F. D'Souza, T. Thomas, Z. Eltahir, A. P. Griffiths, and J. N. Baxter The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-{kappa}B activation in oesophageal cells, with a mechanism of action involving ROS Mutagenesis, September 1, 2008; 23(5): 399 - 405. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Pech, A Behrens, A May, L Nachbar, L Gossner, T Rabenstein, H Manner, E Guenter, J Huijsmans, M Vieth, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus Gut, September 1, 2008; 57(9): 1200 - 1206. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Y. Zhang, X. Zhang, X. Chen, D. Thomas, K. Hormi-Carver, F. Elder, S. J. Spechler, and R. F. Souza Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G470 - G478. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Souza, K. Krishnan, and S. J. Spechler Acid, Bile, and CDX: the ABCs of making Barrett's metaplasia Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G211 - G218. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shibata, T. Matsuda, W. Ajiki, and T. Sobue Trend in Incidence of Adenocarcinoma of the Esophagus in Japan, 1993-2001 Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 464 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rizzetto, S.R. DeMeester, J.A. Hagen, C.G. Peyre, J.C. Lipham, and T.R. DeMeester En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1228 - 1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Nancarrow, H. Y. Handoko, B. M. Smithers, D. C. Gotley, P. A. Drew, D. I. Watson, A. D. Clouston, N. K. Hayward, D. C. Whiteman, and for the Australian Cancer Study and the Study of D Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High-Density Single-Nucleotide Polymorphism Arrays Cancer Res., June 1, 2008; 68(11): 4163 - 4172. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Blaser Understanding Microbe-Induced Cancers Cancer Prevention Research, June 1, 2008; 1(1): 15 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-J. Yen, J. G. Izzo, D.-F. Lee, S. Guha, Y. Wei, T.-T. Wu, C.-T. Chen, H.-P. Kuo, J.-M. Hsu, H.-L. Sun, et al. Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma Cancer Res., April 15, 2008; 68(8): 2632 - 2640. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 727 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie No Association between hOGG1, XRCC1, and XPD Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, or Esophageal Adenocarcinoma: Results from the Factors Influencing the Barrett's Adenocarcinoma Relationship Case-Control Study Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 736 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. El-Serag Role of obesity in GORD-related disorders Gut, March 1, 2008; 57(3): 281 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Chang, H. Ji, N. J. Birkmeyer, M. B. Orringer, and J. D. Birkmeyer Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): 424 - 429. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Feber, L. Xi, J. D. Luketich, A. Pennathur, R. J. Landreneau, M. Wu, S. J. Swanson, T. E. Godfrey, and V. R. Litle MicroRNA expression profiles of esophageal cancer. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. DeMeester New Options for the Therapy of Barrett's High-Grade Dysplasia and Intramucosal Adenocarcinoma: Endoscopic Mucosal Resection and Ablation versus Vagal-Sparing Esophagectomy Ann. Thorac. Surg., February 1, 2008; 85(2): S747 - S750. [Full Text] [PDF] |
||||
![]() |
D C Whiteman, S Sadeghi, N Pandeya, B M Smithers, D C Gotley, C J Bain, P M Webb, A C Green, and for the Australian Cancer Study Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus Gut, February 1, 2008; 57(2): 173 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Feagins, H. Y. Zhang, X. Zhang, K. Hormi-Carver, T. Thomas, L. S. Terada, S. J. Spechler, and R. F. Souza Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G411 - G417. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A Corley Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut, November 1, 2007; 56(11): 1493 - 1494. [Full Text] [PDF] |
||||
![]() |
A. H H Merry, L. J Schouten, R A. Goldbohm, and P. A van den Brandt Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study Gut, November 1, 2007; 56(11): 1503 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Zhang, X. Zhang, K. Hormi-Carver, L. A. Feagins, S. J. Spechler, and R. F. Souza In Non-neoplastic Barrett's Epithelial Cells, Acid Exerts Early Antiproliferative Effects through Activation of the Chk2 Pathway Cancer Res., September 15, 2007; 67(18): 8580 - 8587. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Freedman, C. C. Abnet, M. F. Leitzmann, T. Mouw, A. F. Subar, A. R. Hollenbeck, and A. Schatzkin A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes Am. J. Epidemiol., June 15, 2007; 165(12): 1424 - 1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Izzo, U. Malhotra, T.-T. Wu, R. Luthra, A. M. Correa, S. G. Swisher, W. Hofstetter, K.S. C. Chao, M.-C. Hung, and J. A. Ajani Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor-{kappa}B Expression Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1200 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Oh, S. R. DeMeester, D. Vallbohmer, R. Mori, H. Kuramochi, J. A. Hagen, J. Lipham, K. D. Danenberg, P. V. Danenberg, P. Chandrasoma, et al. Reduction of Interleukin 8 Gene Expression in Reflux Esophagitis and Barrett's Esophagus With Antireflux Surgery Arch Surg, June 1, 2007; 142(6): 554 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mattioli, A. Ruffato, M. P. Di Simone, B. Corti, A. D'Errico, M. L. Lugaresi, B. Mattioli, and F. D'Ovidio Immunopathological Patterns of the Stomach in Adenocarcinoma of the Esophagus, Cardia, and Gastric Antrum: Gastric Profiles in Siewert Type I and II Tumors Ann. Thorac. Surg., May 1, 2007; 83(5): 1814 - 1819. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fitzgerald Molecular Tools for Predicting the Behavior of Barrett's Esophagus Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 133 - 138. [Full Text] [PDF] |
||||
![]() |
T. Liu, X. Zhang, C.-K. So, S. Wang, P. Wang, L. Yan, R. Myers, Z. Chen, A. P. Patterson, C. S. Yang, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells Carcinogenesis, February 1, 2007; 28(2): 488 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Luthra, J. A. Ajani, J. Izzo, J. Ensor, T.-T. Wu, A. Rashid, L. Zhang, A. Phan, N. Fukami, and R. Luthra Decreased Expression of Gene Cluster at Chromosome 1q21 Defines Molecular Subgroups of Chemoradiotherapy Response in Esophageal Cancers Clin. Cancer Res., February 1, 2007; 13(3): 912 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lao-Sirieix, L. Lovat, and R. C. Fitzgerald Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance Clin. Cancer Res., January 15, 2007; 13(2): 659 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bonde, D. Gao, L. Chen, M. Duncan, T. Miyashita, E. Montgomery, J. W. Harmon, and C. Wei Selective decrease in the DNA base excision repair pathway in squamous cell cancer of the esophagus J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 74 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hormi-Carver, L. A. Feagins, S. J. Spechler, and R. F. Souza All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett's cells Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G18 - G27. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R.E. Rees, B. A. Onwuegbusi, V. E. Save, D. Alderson, and R. C. Fitzgerald In vivo and In vitro Evidence for Transforming Growth Factor-{beta}1-Mediated Epithelial to Mesenchymal Transition in Esophageal Adenocarcinoma Cancer Res., October 1, 2006; 66(19): 9583 - 9590. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. de Almeida Simao, G. L. De Bonis Almeida Simoes, F. S. Ribeiro, D. A. de Paula Cidade, N. A. Andreollo, L. R. Lopes, J. M. B. Macedo, R. Acatauassu, A. M. R. Teixeira, I. Felzenszwalb, et al. Lower expression of p14ARF and p16INK4a correlates with higher DNMT3B expression in human oesophageal squamous cell carcinomas Human and Experimental Toxicology, September 1, 2006; 25(9): 515 - 522. [Abstract] [PDF] |
||||
![]() |
K. L. Wang, T.-T. Wu, E. Resetkova, H. Wang, A. M. Correa, W. L. Hofstetter, S. G. Swisher, J. A. Ajani, A. Rashid, S. R. Hamilton, et al. Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association with Poor Outcome Clin. Cancer Res., August 1, 2006; 12(15): 4598 - 4604. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Akre, L. Forssell, M. Kaijser, I. Noren-Nilsson, J. Lagergren, O. Nyren, and A. Ekbom Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 867 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kubo and D. A. Corley Body Mass Index and Adenocarcinomas of the Esophagus or Gastric Cardia: A Systematic Review and Meta-analysis. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 872 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vallbohmer, J. H. Peters, H. Kuramochi, D. Oh, D. Yang, D. Shimizu, S. R. DeMeester, J. A. Hagen, P. T. Chandrasoma, K. D. Danenberg, et al. Molecular Determinants in Targeted Therapy for Esophageal Adenocarcinoma Arch Surg, May 1, 2006; 141(5): 476 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Gonzalez, P. Jakszyn, G. Pera, A. Agudo, S. Bingham, D. Palli, P. Ferrari, H. Boeing, G. del Giudice, M. Plebani, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst, March 1, 2006; 98(5): 345 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Jansson, N Plato, A L V Johansson, O Nyren, and J Lagergren Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma Occup. Environ. Med., February 1, 2006; 63(2): 107 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jaiswal, C. Lopez-Guzman, R. F. Souza, S. J. Spechler, and G. A. Sarosi Jr Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G335 - G342. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Dellon and N. J. Shaheen Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival? J. Clin. Oncol., July 10, 2005; 23(20): 4478 - 4482. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Forman Re: The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence J Natl Cancer Inst, July 6, 2005; 97(13): 1013 - 1014. [Full Text] [PDF] |
||||
























